Meeting
2023 ASCO Annual Meeting
Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study.
Authors
Kazuomi Ueshima
Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan
Kazuomi Ueshima , Masatoshi Kudo , Kaoru Tsuchiya , Naoya Kato , Tatsuya Yamashita , Shigeo Shimose , Kazushi Numata , Yuzo Kodama , Yasuhito Tanaka , Hidekatsu Kuroda , Shinji Itoh , Hiroshi Aikata , Atsushi Hiraoka , Michihisa Moriguchi , Yoshiyuki Wada , Kazuhiko Nakao , Ryosuke Tateishi , Sadahisa Ogasawara , Kouji Yamamoto , Masafumi Ikeda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Local-Regional Disease
Clinical Trial Registration Number
071200051
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4125)
DOI
10.1200/JCO.2023.41.16_suppl.4125
Abstract #
4125
Poster Bd #
446
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
REPLACEMENT trial in progress: Combination therapy with atezolizumab plus bevacizumab for TACE unsuitable patients with beyond up-to-seven criteria in intermediate stage hepatocellular carcinoma: A phase II study.
First Author: Kazuomi Ueshima
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug (casdozo, SRF388) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced, or metastatic hepatocellular carcinoma (uHCC).
First Author: Daneng Li
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Achievement of cancer- and treatment-free status by atezolizumab plus bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-stage hepatocellular carcinoma: A multicenter cohort study.
First Author: Masatoshi Kudo
Poster
2022 ASCO Annual Meeting
ACCRU-GI-2008: A phase II randomized study of atezolizumab (Atezo) plus a multi-kinase inhibitor (MKI) versus MKI alone in patients with unresectable advanced hepatocellular carcinoma (aHCC) who previously received atezolizumab plus bevacizumab (Bev).
First Author: Wen Wee Ma